All News

Viruses that have been linked to Bell's palsy include those that cause cold sores and genital herpes (herpes simplex); Chickenpox and shingles (herpes zoster); and infectious mononucleosis.

Those who are younger than aged 40 years tend to regain these senses at higher rates than those who are older.

A town hall meeting with representatives from the agencies emphasized the effectiveness and likelihood of getting a third dose of the vaccine.

When it comes to maximizing therapeutic opportunities for the treatment of individuals with toxoplasmosis, pharmacists and other health care professionals understand the value of care coordination.

The existence of immunoglobulin G antibodies specifically indicates recent or prior infection and can help identify individuals with an adaptive immune response to SARS-CoV-2.

Soliman is ecstatic to celebrate the 4th annual #WomenPharmacistDay and that the pharmacy landscape is continuing to recognize the contributions of women in the field.

Vaccine efficacy was 93% against the Delta variant at 1 month after the 2-dose vaccine regimen, although it fell to 53% after 4 months.

New legislation in New York state seeks to address flaws in prescription drug distribution system.

Patients use prescription niacin (Niacor, Niaspan) to help control their cholesterol.

Nusinersen (Spinraza) is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

In a study, individuals who were taking prucalopride had better memory tests and fMRI scans indicating enhanced brain activity in relation to cognition.

Respiratory infections can become a problem in muscular dystrophy, therefore immunizations for pneumonia and influenza are vital.

The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.

The phase 3 ENSEMBLE 2 study found that a booster of Johnson & Johnson’s single-shot vaccine administered 56 days after the primary dose provided 94% protection against symptomatic COVID-19.

AZD7442 (AstraZeneca), a long-acting antibody combination, reduced the risk of developing symptomatic COVID-19 by 77% compared to placebo.

ADHD Awareness Months brings attention to a common, but still somewhat misunderstood condition that pharmacists encounter on a near daily basis.

Pharmacists working in the community setting are practicing public health pharmacy practice on a daily basis, but probably just didn’t have a name for it.

This approval will provide further treatment options for younger children living with HIV, according to a ViiV press release.

Ten quiz questions to assess your knowledge on common symptoms and treatments for prostate cancer.

Isatuximab-irfc (Sarclisa; sanofi-aventis) provides patients with another option for treatment and significantly reduces the risk of disease progression or death.

Labcorp’s collection kit can simultaneously detect the coronavirus and influenza A/B in individuals aged 2 years and older, and results can be determined in 1 to 2 days.

With the arrival of flu and cold season, note the differences between symptoms for both illnesses.

Vitamin B5 can aalso be obtained from a healthy diet of broccoli, cabbage, white and sweet potatoes, whole-grain cereals, mushrooms, nuts, beans, peas, lentils, meats, and poultry.

Ruxolitinib is indicated for intermediate or high-risk myelofibrosis, polycythemia vera, steroid-refractory acute graft-versus-host disease, and chronic graft-versus-host disease.

Senator Scott Wiener, discusses the California Senate Bill 519 he co-authored, which is the first and most expansive psychedelic decriminalization bill to go through a state legislature.

Act 406 Allows Community-Pharmacy Service Delivery; HHS Follows With Groundbreaking Ninth PREP Amendment

Oncology pharmacists can affect not only the efficacy of advancements in our health care system but also the scope of health care progress in our country.

Study results show KNT-127 is a promising therapeutic option and enhances the anti-inflammatory response.

Growing demand for specialty care, shifting prescriber habits, and new reimbursement models have forced stakeholders to adjust practices to optimize patient outcomes.

The designation was based on data from the DESTINY-Breast03 phase 3 trial, and this is now the second BTD for trastuzumab deruxtecan in breast cancer, bringing its total number of BTDs to 4, according to an AstraZeneca press release.